Document is current

Article History

Received: 10 October 2022

Accepted: 31 May 2023

First Online: 26 June 2023

Declarations

:

: All animal experiments were performed in compliance with the National Institutes of Health guidelines and were approved by the Institutional Animal Care and Use Committees (IACUC) of the University of California, San Francisco and Oregon Health & Science University.

: Not applicable.

: R.L. Vonderheide is an inventor on a licensed patent relating to cancer cellular immunotherapy and cancer vaccines, and receives royalties for a licensed research-only monoclonal antibody. He is a member of the Lustgarten Therapeutics Advisory working group. R.L. Vonderheide reports having received consulting fees or honoraria from Medimmune and Verastem; and research funding from Fibrogen, Janssen, and Lilly.L.M. Coussens is a paid consultant for Cell Signaling Technologies, AbbVie Inc., and Shasqi Inc., received reagent and/or research support from Plexxikon Inc., Pharmacyclics, Inc., Acerta Pharma, LLC, Deciphera Pharmaceuticals, LLC, Genentech, Inc., Roche Glycart AG, Syndax Pharmaceuticals Inc., Innate Pharma, NanoString Technologies, and Cell Signaling Technologies, is a member of the Scientific Advisory Boards of Syndax Pharmaceuticals, Carisma Therapeutics, Zymeworks, Inc, Verseau Therapeutics, Cytomix Therapeutics, Inc., Hibercell., Inc., Alkermes, Inc., and Kineta Inc, and is a member of the Lustgarten Therapeutics Advisory working group.P.T. Spellman is a paid consultant from Natera and Foundation Medicine Inc.A.A. Margolin is a Venture Partner at Khosla Ventures and Chief Executive Officer at NextVivo, Inc. and was previously Chief of Data Science at Sema4, Inc.No potential conflicts of interest were disclosed by the other authors.